Articles tagged with 'PR' | BIOTRONIK

BIOTRONIK - Archive (PR)

2018
17
December
2018
| 00:00 Europe/Amsterdam
BIOTRONIK has announced first enrollment in a multicenter study that aims to demonstrate that a two-lead cardiac resynchronization therapy (CRT) system with atrial sensing is at least as effective as a conventional three-lead system. BIOTRONIK’s CRT-...
Read more
Tags
PR
CRM
CRT
25
September
2018
| 00:00 Europe/Amsterdam
Investigators unveiled clinical data from the independent BIONYX1 and SORT OUT IX2 all-comers trials which respectively compared durable polymer Resolute Onyxb and polymer-free BioFreedomc to bioresorbable polymer Orsiro. In both studies, patients...
Read more
21
June
2018
| 00:00 Europe/Amsterdam
Today BIOTRONIK and GenesisCare started a three-year strategic partnership to enhance outcomes for cardiac patients in Australia. The new partners will initiate interdisciplinary research projects focusing on better data sharing, care pathways and in...
Read more
Tags
PR
CRM
24
May
2018
| 00:00 Europe/Amsterdam
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials session by Dr. Marlies M. Kok, Thoraxcentrum Twente, MST, Enschede, the Netherlands and simultaneously published in EuroInterventi...
Read more
Tags
PR
VI
26
April
2018
| 00:00 Europe/Amsterdam
BIOTRONIK announced the latest results of three lower limb clinical trials – BIOLUX P-III, BIOFLEX PEACE and BIOLUX 4EVER ...
Read more
Tags
PR
16
March
2018
| 00:00 Europe/Amsterdam
BIOTRONIK unveiled its first-ever digital education app today, just ahead of the company’s appearance at the 2018 European Heart Rhythm Association (EHRA) Congress in Barcelona. The Cardiac Device Expert App is available on iOS and Android platfor...
Read more
Tags
PR
13
March
2018
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that patient enrollment for the BIOSTEMI study has been completed. STEMI is a potentially fatal type of heart attack, caused by prolonged obstruction of blood supply in the heart. More than 730,000 cardiac artery disease (CA...
Read more
07
March
2018
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the company’s MRI AutoDetect technology has been named a finalist in the 2018 South by Southwest® (SXSW®) Conference & Festival Interactive Innovation Awards, highlighting BIOTRONIK’s dedication to innovation that matters fo...
Read more
Tags
PR
01
February
2018
| 00:00 Europe/Amsterdam
The CASTLE-AF study—described as “potentially guideline-changing”, has been published in the New England Journal of Medicine .1 The trial, conducted with BIOTRONIK’s support, shows a 38 percent reduction in the composite endpoint of all-cause mortal...
Read more
Tags
PR
2017
02
November
2017
| 00:00 Europe/Amsterdam
BIOTRONIK’s Orsiro1 drug-eluting stent (DES) demonstrated high long-term safety and clinical performance according to 60-month follow-up data presented during TCT 2017. Data from the BIOFLOW-II randomized controlled trial was presented in a poster...
Read more
31
October
2017
| 00:00 Europe/Amsterdam
Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market. In addition, clinical and preclinical data presented about Magmaris2 reinforce the cas...
Read more
09
October
2017
| 00:00 Europe/Amsterdam
BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical performance of a new coronary stent in de novo coronary artery lesions. On September 28, first Dr. Marco Moccetti, Cardiocentro Tici...
Read more
04
October
2017
| 00:00 Europe/Amsterdam
BIOTRONIK’s exclusive rate responsive technology, Closed Loop Stimulation (CLS) has shown to reduce fainting in pacemaker patients with vasovagal syncope up to sevenfold. Results from the SPAIN study, the first prospective double-blind placebo-contro...
Read more
18
September
2017
| 00:00 Europe/Amsterdam
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce restenosis rates, according to results from various BIOTRONIK studies presented at the 2017 congress of the Cardiovascular and Int...
Read more
29
August
2017
| 00:00 Europe/Amsterdam
The European Heart Rhythm Association (EHRA) released the analytical supplement to the 10th EHRA White Book during the ESC Congress 2017 in Barcelona. Supported by BIOTRONIK, the EHRA White Book is the annual collection of data about the number of...
Read more
28
August
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced data from the BIOFLOW-V randomized trial comparing Orsiro1 and Xience2 drug-eluting stents (DES) with 12-month target lesion failure (TLF) as the primary endpoint proving non-inferiority. Results presented at the European So...
Read more
27
August
2017
| 00:00 Europe/Amsterdam
Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause mortality and hospitalization for worsening heart failure, when heart failure patients with atrial fibrillation (AF) are treated with catheter ablation, ...
Read more
24
August
2017
| 00:00 Europe/Amsterdam
Cardiology experts will present conclusive results from various BIOTRONIK studies at the European Society of Cardiology’s ESC Congress 2017. The presentations and discussions will shed light on recent advances in the treatment of atrial fibrillati...
Read more
21
August
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA approval and commercial availability of Edora HF-T QP, an MR conditional quadripolar (QP) cardiac resynchronization therapy pacemaker (CRT-P) with MRI AutoDetect technology. With a volume of 15 cc, Edora HF-T QP is th...
Read more
03
August
2017
| 00:00 Europe/Amsterdam
BIOTRONIK’s highest performing cardiac resynchronization therapy defibrillator (CRT-D) is now available in Japan. With several key technologies, the Intica 7 HF-T QP has been developed to offer physicians all-inclusive and individualized solutions fo...
Read more
19
July
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA approval and availability of the Intica DX and Intica cardiac resynchronization therapy (CRT)-DX implantable cardioverter defibrillator (ICD) systems. The launch of Intica CRT-DX extends the proven benefits of BIOTRONIK’...
Read more
10
July
2017
| 00:00 Europe/Amsterdam
BIOTRONIK has announced the launch of its Evity cardiac resynchronization therapy pacemaker (CRT-P) in the Japanese market. It is the company’s highest performing CRT-P with a battery life of almost 10 years. Quadripolar technology allows for incr...
Read more
03
July
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the results of the BIOFLEX-I clinical study and availability of Pulsar-18 for the treatment of patients with peripheral artery disease (PAD). Pulsar-18 is the only superficial femoral artery (SFA) self-expanding stent app...
Read more
20
June
2017
| 00:00 Europe/Amsterdam
Physicians exchanged ideas on MR conditional devices in the scientific symposium “Clinical Decision Making in Electrophysiology/ Arrhythmias” at the Europace-Cardiostim 2017 congress today. The panel represented an all-female faculty of electrophysio...
Read more
19
June
2017
| 00:00 Europe/Amsterdam
Experts in heart failure management gathered today to discuss varying scientific evidence in their field and how to transfer results into clinical practice. The BIOTRONIK symposium “CRT in 2017: Remaining Challenges and New Opportunities in Heart Fai...
Read more
13
June
2017
| 00:00 Europe/Amsterdam
BIOTRONIK received CE approval for 3 tesla (T) full-body scans (FBS) with its latest range of MR conditional pacemaker systems. Patients implanted with single- and dual-chamber pacemakers from the Edora/Evity/Enitra series can now benefit from ultra-...
Read more
07
June
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the availability of the Edora line of devices, the company’s first available pacemaker series featuring BIOTRONIK’s MRI AutoDetect technology. Edora SR-T is the smallest MR conditional pacemaker with automated MRI detecti...
Read more
11
May
2017
| 00:00 Europe/Amsterdam
Results now published in the European Heart Journal show BIOTRONIK Home Monitoring® reduces the risk of all-cause mortality in ICD patients after one year by 38 percent. The TRUECOIN study also found a 36 percent reduction in the combined risk of all...
Read more
08
May
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the availability of the first FDA approved cardiac rhythm management (CRM) devices with technology that automatically recognizes when a patient enters an MRI environment. MRI AutoDetect is another example of BIOTRONIK’s comm...
Read more
08
May
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA approval of the company’s MultiPole Pacing (MPP) technology, providing physicians with additional treatment options for heart failure patients who have been non-responsive to cardiac resynchronization therapy (CRT).1 MPP...
Read more